Neoadjuvant chemotherapy for metastatic colorectal cancer to the liver: From chemotherapy to targeting therapy

Hepatobiliary and Pancreatic Diseases International

Volumn 7, Issue 6, 2008, Pages 569-570

  Teng, Li Song ^a   Zheng, Yi ^a   Zhang, Jing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; INTERDISCIPLINARY COMMUNICATION; LIVER METASTASIS; LIVER RESECTION; MONOTHERAPY; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY;

EID: 57849090878     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (9)

1. American Cancer Society. Cancer facts and figures 2008. Atlanta: American Cancer Society; 2008. Available from: URL: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf
2. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-522.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
5. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008;206:96-106.
6. Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007;25:5225-5232.
7. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Zampino M, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007;25(suppl): 4035.
8. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008;26(suppl):2.
9. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008;26(suppl):4000.